An empirical predictive model for determining the aqueous solubility of BCS class IV drugs in amorphous solid dispersions
CONCLUSION: The developed empirical model demonstrated robustness and predicted the aqueous solubility of model drugs from the ASDs of model polymer matrices with an accuracy greater than 80%.PMID:38318700 | DOI:10.1080/03639045.2024.2315477 (Source: Drug Development and Industrial Pharmacy)
Source: Drug Development and Industrial Pharmacy - February 6, 2024 Category: Drugs & Pharmacology Authors: Sridivya Raparla Charina Lampa Xiaoling Li Bhaskara R Jasti Source Type: research
Design, synthesis and in silico insights of novel 1,2,3-triazole benzenesulfonamide derivatives as potential carbonic anhydrase IX and XII inhibitors with promising anticancer activity
Bioorg Chem. 2024 Mar;144:107154. doi: 10.1016/j.bioorg.2024.107154. Epub 2024 Feb 1.ABSTRACTNovel 1,2,3-triazole benzenesulfonamide derivatives were designed as inhibitors for the tumor- related hCA IX and XII isoforms. Most of the synthesized compounds showed good inhibitory activity against hCA IX and hCA XII isoforms. Compounds 4d, 5h and 6b, exhibited remarkable activity as hCA IX inhibitors, with Ki values in the range of 0.03 to 0.06 µM, more potent than AAZ. Additionally, compounds 5b and 6d, efficiently inhibited hCA XII isoform, with Ki value of 0.02 µM, respectively, similar to AAZ. Further investigation for t...
Source: Bioorganic Chemistry - February 3, 2024 Category: Chemistry Authors: Marwa M Abdelhakeem Martha M Morcoss Dina A Hanna Phoebe F Lamie Source Type: research
Systemic lupus erythematosus with chronic persistent intracranial hypertension: A case report
CONCLUSION: Systemic lupus erythematosus with intracranial hypertension is a rare manifestation of SLE, which is not completely parallel to SLE activity. Headache and papilledema were the most common presenting symptoms. Different from previous reported cases, our patient had poor response to treatments, showing chronic and persistent characteristics.PMID:38285490 | DOI:10.1177/09612033241230734 (Source: Lupus)
Source: Lupus - January 29, 2024 Category: Rheumatology Authors: Minchao Zou Xinyu Jiang Haifeng Chen Fenghong Yuan Source Type: research
Acetazolamide for acute kidney injury in patients undergoing high dose methotrexate therapy: a systematic review and meta-analysis
CONCLUSIONS: This systematic review showed no significant difference between acetazolamide and standard care treatment regarding urine alkalinization time and AKI rate in adult patients receiving high dose methotrexate. We suggest performing a large blinded, randomized, controlled trial to evaluate the potential benefits of this low-cost medication.PMID:38265601 | DOI:10.1007/s40620-023-01850-2 (Source: Journal of Nephrology)
Source: Journal of Nephrology - January 24, 2024 Category: Urology & Nephrology Authors: Hong Hieu Truong Swetha Reddy Mariam Charkviani Nasrin Nikravangolsefid Jacob Ninan Leslie Hassett Kianoush Banaei Kashani Juan Pablo Domecq Source Type: research
Effect of altitude and acetazolamide on postural control in healthy lowlanders 40 years of age or older. Randomized, placebo-controlled trial
Conclusion: In healthy individuals, 40 years of age or older, postural control was impaired after spending a night at 3,100 m. The altitude-induced deterioration of postural control was mitigated by acetazolamide, most likely due to the associated improvement in oxygenation. (Source: Frontiers in Physiology)
Source: Frontiers in Physiology - January 4, 2024 Category: Physiology Source Type: research
Effects of acetazolamide combined with remote ischemic preconditioning on risk of acute mountain sickness: a randomized clinical trial
We aimed to determine whether and how the combination of acetazolamide and remote ischemic preconditioning (RIPC) reduced the incidence and severity of acute mountain sickness (AMS). (Source: BMC Medicine)
Source: BMC Medicine - January 2, 2024 Category: Internal Medicine Authors: Moqi Liu, Xueqiao Jiao, Rui Li, Jialu Li, Lu Wang, Liyan Wang, Yishu Wang, Chunmei Lv, Dan Huang, Ran Wei, Liming Wang, Xunming Ji and Xiuhai Guo Tags: Research article Source Type: research
In acute decompensated HF, adding acetazolamide to IV loop diuretics reduced congestion at 3 d across eGFR levels
Ann Intern Med. 2024 Jan 2. doi: 10.7326/J23-0111. Online ahead of print.ABSTRACTMeekers E, Dauw J, Martens P, et al. Renal function and decongestion with acetazolamide in acute decompensated heart failure: the ADVOR trial. Eur Heart J. 2023;44:3672-3682. 37623428.PMID:38163366 | DOI:10.7326/J23-0111 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - January 1, 2024 Category: Internal Medicine Authors: Daniel Rospert Donald A Molony Source Type: research
In acute decompensated HF, adding acetazolamide to IV loop diuretics reduced congestion at 3 d across eGFR levels
Ann Intern Med. 2024 Jan 2. doi: 10.7326/J23-0111. Online ahead of print.ABSTRACTMeekers E, Dauw J, Martens P, et al. Renal function and decongestion with acetazolamide in acute decompensated heart failure: the ADVOR trial. Eur Heart J. 2023;44:3672-3682. 37623428.PMID:38163366 | DOI:10.7326/J23-0111 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - January 1, 2024 Category: Internal Medicine Authors: Daniel Rospert Donald A Molony Source Type: research
In acute decompensated HF, adding acetazolamide to IV loop diuretics reduced congestion at 3 d across eGFR levels
Ann Intern Med. 2024 Jan 2. doi: 10.7326/J23-0111. Online ahead of print.ABSTRACTMeekers E, Dauw J, Martens P, et al. Renal function and decongestion with acetazolamide in acute decompensated heart failure: the ADVOR trial. Eur Heart J. 2023;44:3672-3682. 37623428.PMID:38163366 | DOI:10.7326/J23-0111 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - January 1, 2024 Category: Internal Medicine Authors: Daniel Rospert Donald A Molony Source Type: research
In acute decompensated HF, adding acetazolamide to IV loop diuretics reduced congestion at 3 d across eGFR levels
Ann Intern Med. 2024 Jan 2. doi: 10.7326/J23-0111. Online ahead of print.ABSTRACTMeekers E, Dauw J, Martens P, et al. Renal function and decongestion with acetazolamide in acute decompensated heart failure: the ADVOR trial. Eur Heart J. 2023;44:3672-3682. 37623428.PMID:38163366 | DOI:10.7326/J23-0111 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - January 1, 2024 Category: Internal Medicine Authors: Daniel Rospert Donald A Molony Source Type: research
In acute decompensated HF, adding acetazolamide to IV loop diuretics reduced congestion at 3 d across eGFR levels
Ann Intern Med. 2024 Jan 2. doi: 10.7326/J23-0111. Online ahead of print.ABSTRACTMeekers E, Dauw J, Martens P, et al. Renal function and decongestion with acetazolamide in acute decompensated heart failure: the ADVOR trial. Eur Heart J. 2023;44:3672-3682. 37623428.PMID:38163366 | DOI:10.7326/J23-0111 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - January 1, 2024 Category: Internal Medicine Authors: Daniel Rospert Donald A Molony Source Type: research
In acute decompensated HF, adding acetazolamide to IV loop diuretics reduced congestion at 3 d across eGFR levels
Ann Intern Med. 2024 Jan 2. doi: 10.7326/J23-0111. Online ahead of print.ABSTRACTMeekers E, Dauw J, Martens P, et al. Renal function and decongestion with acetazolamide in acute decompensated heart failure: the ADVOR trial. Eur Heart J. 2023;44:3672-3682. 37623428.PMID:38163366 | DOI:10.7326/J23-0111 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - January 1, 2024 Category: Internal Medicine Authors: Daniel Rospert Donald A Molony Source Type: research
Loop gain response to increased cerebral blood flow at high altitude
CONCLUSION: Pharmacological elevation in CBF significantly reduced LG and severity of CSA. We speculate the effect was on HCVR "controller gain," rather than "plant gain," because PaCO2 and VE were unchanged. An effect via reduced circulation time is unlikely, as the respiratory-cycle length did not change.PMID:38085496 | DOI:10.1007/s11325-023-02956-4 (Source: Sleep and Breathing)
Source: Sleep and Breathing - December 12, 2023 Category: Sleep Medicine Authors: Andrew Burgess Gareth Andrews Katie M E Colby Samuel J E Lucas Kate Sprecher Joseph Donnelly Philip N Ainslie Aparna S Basnet Keith R Burgess Source Type: research
Loop gain response to increased cerebral blood flow at high altitude
CONCLUSION: Pharmacological elevation in CBF significantly reduced LG and severity of CSA. We speculate the effect was on HCVR "controller gain," rather than "plant gain," because PaCO2 and VE were unchanged. An effect via reduced circulation time is unlikely, as the respiratory-cycle length did not change.PMID:38085496 | DOI:10.1007/s11325-023-02956-4 (Source: Sleep and Breathing)
Source: Sleep and Breathing - December 12, 2023 Category: Sleep Medicine Authors: Andrew Burgess Gareth Andrews Katie M E Colby Samuel J E Lucas Kate Sprecher Joseph Donnelly Philip N Ainslie Aparna S Basnet Keith R Burgess Source Type: research
Loop gain response to increased cerebral blood flow at high altitude
ConclusionPharmacological elevation in CBF significantly reduced LG and severity of CSA. We speculate the effect was on HCVR “controller gain,” rather than “plant gain,” because PaCO2 andVE were unchanged. An effect via reduced circulation time is unlikely, as the respiratory-cycle length did not change. (Source: Sleep and Breathing)
Source: Sleep and Breathing - December 12, 2023 Category: Respiratory Medicine Source Type: research
